Back

Cardiovascular risk factors and outcomes in patients with thymoma receiving cancer therapy

21 June 2025 (13:00 - 14:00)
Organised by: Logo
Congress Presentation Part of: Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Inbar Nardi Agmon

Chaim Sheba Medical Center, Tel Aviv Universty, Ramat Gan (Israel)

8 More presentations in this session

Presentation thumbnail
Right ventricular dysfunction in hematologic patients exposed to Chimeric Antigen Receptor (CAR)-T cells therapy: results from the prospective CARdio-TOX study.
Doctor L. Amore (Rome, IT)
Abstract Slides
Presentation thumbnail
Abatacept vs. conventional therapy in immune checkpoint inhibitor-associated myocarditis
Doctor T. Imaoka (Kashiwa, JP)
Abstract Slides
Presentation thumbnail
Cardiac dysfunction in patients with kidney cancer receiving immunotherapy
Doctor M. Spisarova (Olomouc, CZ)
Abstract Slides
Presentation thumbnail
High incidence of immune checkpoint inhibitor therapy related subclinical cardiac dysfunction in patients with extracardiac immune related adverse events
Associate Professor R. Mincu (Essen, DE)
Abstract Slides
Presentation thumbnail
Mycophenolate mofetil as second-line therapy for steroid-refractory ICI-induced myocarditis
Doctor S. Jimenez-Marrero (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 13:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources